Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411813 · ClinicalTrials.gov registry record
Alprazolam and Eating Behavior in Anorexia Nervosa
A clinical trial of Anorexia Nervosa, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT01411813: Completed study of Anorexia Nervosa, sponsored by New York State Psychiatric Institute.
NCT01411813 is a study of Anorexia Nervosa that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 19 participants, below the 950-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01411813, a study of Anorexia Nervosa, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the role of anxiety in food intake among patients with AN by measuring caloric intake in a standardized, laboratory meal with alprazolam versus a placebo. Patients will participate in two test meal sessions, one after receiving alprazolam and one after receiving a placebo. Patients will be administered psychological measures of anxiety, mood, and eating behavior. Primary outcomes include caloric intake in a laboratory test meal and pre-meal anxiety levels.
Primary Outcome
Assessment of caloric intake after taking alprazolam or placebo.
Conditions Studied
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-10 |
What the finished NCT01411813 record still lists
NCT01411813 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 950-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Anorexia Nervosa appearing as the primary indexed condition, and to 0 interventions.
NCT01411813 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01411813 about?
NCT01411813 is a clinical study titled "Alprazolam and Eating Behavior in Anorexia Nervosa". This study examines the role of anxiety in food intake among patients with AN by measuring caloric intake in a standardized, laboratory meal with alprazolam versus a placebo. Patients will participate in two test meal sessions, one after receiving alprazolam and one after receiving a placebo. Patien...
What is the current status of trial NCT01411813?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2010-11. Estimated completion is 2011-10.
What conditions does trial NCT01411813 study?
This clinical trial studies the following conditions: Anorexia Nervosa.
Who is sponsoring clinical trial NCT01411813?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01411813 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anorexia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01411813's enrollment target sits among peer trials
19 40th of 43 higher than 4 of 43 other Anorexia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
RECRUITING · NA
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa
RECRUITING · NA
-
Eating Disorders Genetics Initiative 2
RECRUITING
-
Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia